We are excited to recognize two historic milestones that resonate deeply with the International Cytokine and Interferon Society: the 50th anniversary of the term “cytokine” and the 70th anniversary of the introduction of “Interferons.” Contributed by Valeriya Smaliy and Susan Carpenter, Ph.D., University of California at Santa Cruz It was [READ MORE]
BMS Session at Cytokines 2024 / KAI 2024 Joint Meeting – Inflammasome-activated cytokines in human diseases
Scott W. Canna, MD [READ MORE]
The International Cytokine & Interferon Society is pleased to announce that we have partnered with North America’s largest B2B publisher, Multiview, to produce our email newsletter, Signals+. We know how important it is to have direct access to the latest information, trends, and developments in our ever-changing field of practice. [READ MORE]
By Supreet Agarwal Cytokines represent the major class of all the soluble ligands targeted by FDA-approved drugs Major cytokines’ (interferons, interleukins and chemokines) targeted therapies Figures adapted from: Attwood, M.M., Jonsson, J., Rask-Andersen, M. et al. Soluble ligands as drug targets. Nat Rev Drug Discov 19, 695–710 (2020). https://doi.org/10.1038/s41573-020-0078-4 Cytokines based therapies approved in [READ MORE]
International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy
